Shares of Novavax have come under renewed scrutiny as analysts update their fair value estimates in light of recent strategic shifts. The consensus analyst price target for Novavax stock has edged ...

Wondering if Novavax is a hidden bargain or just another biotech roller coaster? You are not alone, and getting to the bottom of its real value is more important than ever. Despite plenty of buzz, ...

IAVI reports its single-dose Lassa fever vaccine is safe and effective, paving way for advanced trials across West Africa.

NORTHAMPTON, MA / ACCESS Newswire / November 4, 2025 / Public policies are central factors in determining healthcare interventions and access to medicines and treatment. Viatris leverages our global ...

Pfizer Inc said on Monday its experimental vaccine was more than 90% effective in preventing COVID-19 based on initial data from a large study, a major victory in the fight against the pandemic.

Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial ...

Novavax is slimming down again by striking a deal to transfer the lease to its Maryland corporate headquarters to AstraZeneca in exchange for nearly $60 million. The Gaithersburg, Maryland-based ...

Oct 22 (Reuters) - Novavax (NVAX.O), opens new tab said on Wednesday it has signed agreements to transfer one of its U.S.-based facilities and sell certain equipment for $60 million, without sharing ...

Novavax is pushing ahead with plans to slim down with a deal to offload one its locations in Maryland and surrounding property, which is expected to net $60 million in cash for the vaccine maker.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The property was “not needed ...

Novavax (NASDAQ:NVAX) on Wednesday announced an agreement to assign its Gaithersburg, Maryland, facility and certain assets to AstraZeneca (NASDAQ:AZN) as part of two separate deals worth nearly $60M.

Fintel reports that on October 24, 2025, Cantor Fitzgerald initiated coverage of Novavax (NasdaqGS:NVAX) with a Overweight recommendation. Analyst Price Forecast Suggests 59.05% Upside As of September ...